A Safety, Tolerability, Pharmacokinetic And Efficacy Study Of Azithromycin Plus Piperaquine As Intermittent Presumptive Treatment In Pregnant Papua New Guinean Women
Funder
National Health and Medical Research Council
Funding Amount
$345,684.00
Summary
The purpose of this research is to investigate a new antimalarial combination therapy, azithromycin (AZI) plus piperaquine (PQ), for the prevention of malaria infection in pregnant Papua New Guinean women. It is anticipated that these studies will provide sufficient data to determine if AZI-PQ is a suitable alternative treatment option in PNG, and other countries which have similar malaria epidemiology including the presence of drug resistant parasites.
Antibodies Against Erythrocyte Invasion Ligands Of Plasmodium Falciparum And Protection From Malaria
Funder
National Health and Medical Research Council
Funding Amount
$358,184.00
Summary
Malaria is a leading cause of childhood death globally. Malaria parasites infect red blood cells and multiply inside them, resulting in severe illness if untreated. Currently there is no vaccine available and effective treatments are limited. In studies of children in Africa and PNG, we aim to identify immune responses that block infection and growth of malaria in the blood. With this knowledge, vaccines can be designed that target malaria to prevent serious illness and death.
Identifying The Targets Of Protective Immunity To Malaria In Pregnancy
Funder
National Health and Medical Research Council
Funding Amount
$457,267.00
Summary
Malaria in pregnancy is a major cause of disease across many countries. Pregnant women have a high risk of malaria, and large numbers of malaria parasites accumulate in the placenta, which may lead to infant or maternal death. Malaria parasites infect the placenta by producing proteins that enable them to stick to the placenta. These malaria strains causing placental infection generally do not cause disease in non-pregnant individuals. Antibodies to the parasite proteins are produced in response ....Malaria in pregnancy is a major cause of disease across many countries. Pregnant women have a high risk of malaria, and large numbers of malaria parasites accumulate in the placenta, which may lead to infant or maternal death. Malaria parasites infect the placenta by producing proteins that enable them to stick to the placenta. These malaria strains causing placental infection generally do not cause disease in non-pregnant individuals. Antibodies to the parasite proteins are produced in response to placental infection, which may help control the infection and protect against further malaria in pregnancy. However, placental malaria parasites are able to vary the proteins they produce to avoid immune responses. In this project, we will study the parasite strains that cause malaria in pregnancy and the development of antibodies that protect pregnant women against malaria and its complications. We aim to identify the genes and proteins that parasites use to stick to the placenta, and determine how much variation occurs in these proteins. We will also specifically examine the role of one particular candidate gene called var2csa, and its protein, as this has been recently been associated with pregnancy malaria. We will examine how antibodies develop that recognise different proteins and different forms of malaria parasites, and determine the type of antibodies that protect pregnant women taking part in a longitudinal study of malaria in pregnancy in Malawi, Africa. We will also examine how antimalarial drugs taken in pregnancy influence the development of protective antibodies. Through these studies we aim to understand how the immune system combats malaria in pregnancy. This will be important for developing new methods for preventing or treating malaria in pregnancy, and improving child and maternal health.Read moreRead less
Defining The Targets And Function Of Antibodies That Protect Against Malaria In Pregnancy
Funder
National Health and Medical Research Council
Funding Amount
$547,970.00
Summary
Malaria during pregnancy is a major cause of maternal and infant morbidity and mortality globally. In this project we aim to define the targets of antibodies that protect against malaria in pregnancy and understand the importance of antibody function, determine the extent of antigenic diversity, and identify epitopes of protective antibodies. Results will provide critical knowledge on the development of immunity to malaria in pregnancy that will guide vaccine development.